Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
HALDOL (haloperidol decanoate) is a long-acting, depot formulation of a first-generation antipsychotic administered via intramuscular injection. It is indicated for the management of psychotic disorders and schizophrenia, particularly in patients requiring sustained antipsychotic coverage. The drug works as a dopamine antagonist, blocking D2 receptors to reduce psychotic symptoms.
As a legacy product approaching loss of exclusivity, the brand team is likely small and focused on defending market share against newer atypical antipsychotics rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
Working on HALDOL offers limited career growth opportunity, as the product is mature and post-LOE with no new clinical development. Roles are primarily defensive-focused, emphasizing market share retention, customer relationship management, and cost optimization rather than brand building or innovation.
Worked on HALDOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo